The Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and Washington Adventist Hospital, which has plans to relocate to White Oak near the FDA campus, have entered into an agreement to collaborate on drug evaluation and research.

“This agreement builds on the existing relationship between the FDA and Washington Adventist Hospital by allowing additional collaboration with the Center for Drug Evaluation and Research,” said John Whyte, M.D., M.P.H., CDER’s director, Professional Affairs and Stakeholder Engagement. “This continuing partnership is beneficial to the mission of both organizations, particularly CDER’s responsibility to protect patients by assuring the safety, effectiveness, and security of human drugs. We look forward to exploring the new opportunities that result from this collaboration.”

Washington Adventist and FDA

Joyce Newmyer, president, Washington Adventist Hospital with Melanie Keller, executive officer, Center for Drug Evaluation & Research, FDA, along with representatives from WAH & CDER.

The Memorandum of Understanding (MOU) between the hospital and the CDER is the second such agreement between the organizations. In January 2009, an overarching MOU was signed to support medical and scientific progress affecting human health and medicine.

Some of the current collaboration includes:

  • Training and exchange of medical professionals and staff by the two organizations
  • Collaborating on clinical research
  • Sharing facilities and equipment for increased cost efficiencies for scientific research

“Our physicians value the work they’re doing with their FDA colleagues. There is a tremendous opportunity to advance medical research and enhance patient care and safety through this partnership,” said Randall Wagner, M.D., Chief Medical Officer at Washington Adventist Hospital.

By sharing resources and talents, the two organizations say they are opening up new areas of discovery, funding and cooperation that are critically important for keeping both organizations on the leading edge and for protecting and promoting public health.

“We believe continued cooperation with the FDA will further our commitment to provide the best possible health care to the communities we serve,” said Joyce Newmyer, President of Washington Adventist Hospital.